The University of Texas System

Profectus Biosciences, Inc.

Scott C Weaver

Ilya V Frolov

Elena Frolova

Farooq Nasar

Robert B Tesh

Rodion V Gorchakov

Hilda Guzman

Walter Ian Lipkin

Gustavo Palacios

Theresa E Latham

Jesse Erasmus

John H Eldridge

Eryu Wang

David K Clarke

Robert L Seymour

Andrew D Haddow

Demetrius Matassov

Stefan Hamm

Rebecca Nowak

Naomi Forrester

The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions.

Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Certain embodiments are directed to recombinantencoding a heterologous polynucleotide and methods of using the same.

Recombinant isfahan viral vectors

Embodiments are directed compositions related to Eilat virus and uses thereof.

Alphavirus compositions and methods of use

Embodiments are directed compositions related to Eilat virus and uses thereof. Certain aspects are directed to the detection of non-Eilat entities using a chimeric Eilatas a capture agent.

Certain embodiments are directed to Negevirus and their polynucleotides and polypeptides.

[object Object]

The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.

Chimeric sindbis-western equine encephalitis virus and uses thereof

The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, &#x2dc;35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, C30-68, includes two domains with distinguished functions. The integrity of both domains determines not only the intracellular distribution of C, but is also essential for direct capsid function in the inhibition of transcription. The replacement of the N-terminal fragment of Cby its SINV-specific counterpart in VEEV TC-83 genome does not affect virus replication in vitro, but makes it less cytopathic and more attenuated in vivo.

Attenuation of encephalitogenic alphavirus and uses thereof

The present invention discloses a chimeric Chikungunya virus comprising a heterologous alphavirus cDNA fragment and a Chikungunya virus cDNA fragment. The heterologous alphavirus may include but is not limited to Sindbis virus, Eastern equine encephalitis virus or Venezuelan equine encephalitis virus. The present invention also discloses the use of this chimeric Chikungunya virus as vaccines and in serological and diagnostic assays.

Growing community of inventors

Galveston, TX, United States of America

Scott C Weaver